Christine Soden

Christine is a non-executive director of Elementis plc, the Cell and Gene Therapy Catapult, Fertility Focus Limited and Futurenova Limited and has previously served as chair of the audit committee at e-therapeutics plc, an AIM listed technology-based drug discovery platform from 2017 to February 2020 and at Provalis plc, a quoted healthcare business from 2000 to 2005. Christine is a Chartered Accountant and holds a degree in Mathematics from the University of Durham.

Christine Soden is an experienced CFO who brings significant experience in the commercialisation of innovative technology to the Board. She has a strong track record of leading innovative private and public biotechnology, life science and pharmaceutical companies, both private and public.

From 2015-2020 Christine was CFO and Company Secretary of Acacia Pharma Group plc, a public quoted provider of pharmaceutical products designed to improve the outcomes and recovery for surgical patients. Prior to that role, Christine served as CFO and then non-executive Director of AIM-listed Electrical Geodesics, Inc., which was acquired by Philips NV in 2017. Other CFO and finance leadership roles include Optos plc, BTG plc (former FTSE250 constituent), Oxagen Limited and Celltech Chiroscience Group plc, having started her life-sciences career as Financial Controller of Medeva plc.